Related references
Note: Only part of the references are listed.Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers
Pablo Zubiaur et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs
Katherine N. Theken et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy
Jacob T. Brown et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
Zeruesenay Desta et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
The epidemiology of benzodiazepine misuse: A systematic review
Victoria R. Votaw et al.
DRUG AND ALCOHOL DEPENDENCE (2019)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing
R. S. Gammal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system
Carmelo Aguirre et al.
MEDICINA CLINICA (2016)
Insights into CYP2B6-mediated drug-drug interactions
William D. Hedrich et al.
ACTA PHARMACEUTICA SINICA B (2016)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
K. A. Birdwell et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Classics in Chemical Neuroscience: Diazepam (Valium)
Nicholas E. Calcaterra et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
S. A. Scott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification
Andrew Rowland et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2013)
Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
Su-Jun Lee
Frontiers in Genetics (2013)
Inhibitory role for GABA in autoimmune inflammation
Roopa Bhat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Sex Differences in Pharmacokinetics and Pharmacodynamics
Offie P. Soldin et al.
CLINICAL PHARMACOKINETICS (2009)
CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia
S Inomata et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTS):: S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9
MH Court et al.
DRUG METABOLISM AND DISPOSITION (2002)
New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder
DJ Nutt et al.
BRITISH JOURNAL OF PSYCHIATRY (2001)
Share Paper
